Anti-Mouse Thy1.1 (CD90.1) (Clone 19E12) – Purified in vivo GOLD™ Functional Grade

Mouse Thy1.1 transfected cells.

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

19E12 activity is directed against mouse Thy1.1 (CD90.1).

Thy1 is a highly conserved, GPI-linked member of the immunoglobulin superfamily that is important in the immune and nervous systems¹ and involved in T cell activation and cell-cell interactions². The effects of Thy1 are context dependent¹. Thy1 is heavily N-glycosylated with a carbohydrate content of up to 40% of its molecular mass, and its moiety composition varies between tissues as well as between cells of the same lineage in different stages of differentiation. Additionally, Thy1 is found in both membrane-bound and soluble forms, and, in mouse, Thy1 is encoded by two alleles, Thy1.1 and Thy1.2, which are distinguished by a single amino acid at position 89¹. Thy1 deficiency does not compromise immunity², but its presence or absence modulates the phenotypes of certain cancers, fibrotic diseases, and neuronal injury¹. Thy1.1 is an alloantigen of the AKR/J and PL mouse strains².

19E12 was generated by immunizing 129 strain mice with allogeneic AKR SL3 leukemia cells and fusing the resulting lymphocytes with BALB/c MOPC21 NSI/1 myeloma cells³. 19E12 showed specificity for Thy1.1 antigen in cytotoxic assays. Additionally, 19E12 was found to have antitumor activity in (B6 x AKR)F₁ hybrid mice, AKR parental mice³ and AKR/J mice⁴ inoculated with AKR SL2 cells. Antitumor activity was enhanced when administered in combination with rat monoclonal antibody R17 208⁵.

19E12 antibody has been used to create a bispecific hybrid antibody that can focus T cell activity against Thy1.1-expressing tumor cells for lysis in vitro⁶. A biotinylated form has also been used as a tumor pretargeting agent to increase the local concentration and persistence of human tumor necrosis factor alpha on a mouse tumor⁷. 19E12 can also be used to deplete Thy1.1-expressing cells in mice^8,9,10,11,12, both in naturally occurring Thy1.1⁺ T cells and in cells trangenically expressing Thy1.1 due to experimental design. Thy1 is widely used as a marker for thymus T cells¹³, thymus-derived lymphocytes, and lipid rafts in murine T cells².

Thy1.1 is present on the cell surface of mouse thymocytes, T-lymphocytes, peripheral T cells, neurons, bone marrow stem cells, retinal ganglion cells, myoblasts, subsets of fibroblasts, vascular pericytes, epidermal cells, activated endothelial cells, keratinocytes, mesangial cells, and hematopoietic and mesenchymal stem cells.

Interacts with CD45

1 Bradley JE, Ramirez G, Hagood JS. Biofactors. 35(3):258-265. 2009.
2 Haeryfar SM, Hoskin DW. J Immunol. 173(6):3581-3588. 2004.
3 Bernstein ID, Tam MR, Nowinski RC. Science. 207(4426):68-71. 1980.
4 Badger CC, Bernstein ID. J Exp Med. 157(3):828-842. 1983.
5 Sauvage CA, Mendelsohn JC, Lesley JF, et al. Cancer Res. 47(3):747-753. 1987.
6 Staerz UD, Bevan MJ. Proc Natl Acad Sci U S A. 83(5):1453-1457. 1986.
7 Moro M, Pelagi M, Fulci G, et al. Cancer Res. 57(10):1922-1928. 1997.
8 Scott-Browne JP, Shafiani S, Tucker-Heard G, et al. J Exp Med. 204(9):2159-2169. 2007.
9 Badell IR, Kitchens WH, Wagener ME, et al. Am J Transplant. 15(12):3081-3094. 2015.
10 Kim J, Jeong Ryu S, Oh K, et al. Nat Commun. 6:7994. 2015.
11 Liu B, Lee JB, Chen CY, et al. J Immunol. 194(8):3583-3593. 2015.
12 Campisi L, Barbet G, Ding Y, et al. Nat Immunol. 17(9):1084-1092. 2016.
13 Mestas J, Hughes CC. J Immunol. 172(5):2731-2378. 2004.